We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
+4.23%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$290M
AUM Growth
-$94.3M
(-25%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-26.26%
Top 10 Holdings %
Top 10 Hldgs %
69.05%
Holding
35
New
2
Increased
3
Reduced
20
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$6.45M |
| 2 |
AXDX
Accelerate Diagnostics
AXDX
|
+$2.06M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$1.1M |
| 4 |
Fortress Biotech
FBIO
|
+$174K |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$46.5K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$19.2M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$11.4M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$8.62M |
| 4 |
SRNE
Sorrento Therapeutics, Inc.
SRNE
|
+$8.48M |
| 5 |
SPPI
Spectrum Pharmaceuticals Inc
SPPI
|
+$7.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.78% |
| 2 | Miscellaneous | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADYX
26
DELISTED
Adynxx Inc
ADYX
| $1.8M | 0.62% |
13,985
-182
| -1% | -$31.1K |
|
|
CLLS
27
Cellectis
CLLS
$162M
| $1.09M | 0.37% |
35,000
| – | – |
|
|
28
CALL
Sarepta Therapeutics
SRPT
$2.19B
| $626K | 0.22% |
47,300
-131,000
| -73% | -$4.25M |
|
29
Gyre Therapeutics
GYRE
$709M
| $224K | 0.08% |
636
-110
| -15% | -$43.3K |
|
|
30
Acadia Pharmaceuticals
ACAD
$4.61B
| – | – |
-581,900
| Closed | -$19.2M |
|
31
CALL
Heron Therapeutics
HRTX
$59.6M
| – | – |
-500,000
| Closed | -$153K |
|
32
PUT
iShares Russell 2000 ETF
IWM
$76.9B
| – | – |
-1,280,000
| Closed | -$4.98M |
|
|
SCPX
33
DELISTED
Scorpius Holdings, Inc.
SCPX
| – | – |
-1
| Closed | -$1.58M |
|
|
SPPI
34
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| – | – |
-1,315,600
| Closed | -$7.87M |
|
|
KITE
35
PUT
DELISTED
Kite Pharma, Inc.
KITE
| – | – |
-26,000
| Closed | -$113K |
|
Similar funds
GI
AIM
BEI
VNIM
MF
MC
GJL
LCAM
Avoro Capital Advisors's Q4 2015 Portfolio in Review
As of Q4 2015, Avoro Capital Advisors held 35 positions worth $290M, down 25% from $385M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Avoro Capital Advisors withdrew a net $76.2M in Q4 2015, closing 6 positions and reducing 20 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $19.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, Avoro Capital Advisors opened a new position in Neurocrine Biosciences worth $7.18M.
- Avoro Capital Advisors's largest Q4 2015 buy was Neurocrine Biosciences: 127,000 shares worth $7.18M.
- Avoro Capital Advisors added most to Sarepta Therapeutics in Q4 2015, an estimated $1.1M increase.
- Avoro Capital Advisors's biggest Q4 2015 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $11.4M.
- Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q4 2015, selling an estimated $19.2M.
- Avoro Capital Advisors's ten largest holdings make up 69% of its $290M portfolio in Q4 2015.
- Avoro Capital Advisors opened 2 new positions and closed 6 in Q4 2015.
- Avoro Capital Advisors's portfolio value fell 25% quarter-over-quarter to $290M.
Based on Avoro Capital Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.